The federal government’s recent threat to penalize Johnson & Johnson (J&J) for its unapproved 340B rebate model could spark a [...] …
Articles by : William Newton, Associate Editor/Senior Writer
A federal district judge ruled that four drugmakers’ 340B contract pharmacy restrictions—as implemented in 2021—do not violate the 340B statute, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The federal agency that oversees the 340B program today formally warned Johnson & Johnson (J&J) that it must “cease implementation [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Washington, D.C.-based children’s hospital has sued the federal government for authorizing drugmaker Johnson & Johnson (J&J) to perform “unlawful” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four diabetes drugmakers are urging a federal appeals court to uphold a lower court’s decision to dismiss 340B antitrust claims [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The federal government is likely to continue opposing 340B rebate models even as it moves to resolve four separate contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Exclusive
Arkansas Plans to Challenge J&J’s Contested 340B Rebate Proposal for Violation of State Law
Arkansas plans to challenge Johnson & Johnson’s (J&J’s) 340B rebate proposal for violating the state’s law barring drugmaker contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Maryland federal district judge has denied four separate drug industry attempts to block the state’s contract pharmacy access law—marking [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. government is asking a federal district court in Washington, D.C., to rule for drugmakers in four separate lawsuits [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical manufacturer Merck has announced it will refund 340B covered entities for certain overcharges of its inhaler, Proventil HFA, during [...] …